Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Abuse Deterrent Formulation Technologies Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. ‘Abuse-Deterrent Formulation Technologies Market, 2019-2030’…
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
MUNICH & GARCHING, Germany–(BUSINESS WIRE)–ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, announced today that…
Novartis’ company Avexis said that it’s Phase 1/2 Srong study for intrathecal (IT) administration of AVXS-101, showed that patients aged 2 to 5, with spinal muscular atrophy (SMA) Type 2 achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold, at a mean duration of follow-up time of 9.3 months.
Catabasis Pharmaceuticals will present differentiating safety and tolerability profile of Edasalonexent through more than 55 patient years of exposure, from a phase 2 trial, which showed edasalonexent slowed duchenne muscluar dystrophy progression.
– First seven treated patients now ventilator independent and able to rise to a standing position or walk – Continued…
Leading Online Marketplace Will Share Best Practices for Sourcing R&D Services TOKYO–(BUSINESS WIRE)–#fasterscience–Scientist.com, the pharmaceutical industry’s largest online marketplace for…
— Proceeds to Advance Research in Clinical Setting– GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and…